---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-102554"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:41:02.680199+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027

## Summary
- Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.
- Estimated topline results from PROACT 1 by Q3 2027; expects $150-175M expense reduction.
- Cash runway extended to Q1 2027; focused on U.S. market for rilparencel in advanced CKD with type 2 diabetes.
- CEO cites positive REGEN-007 interim data as supporting urgency; RMAT designation granted Oct 2021.

## SEC filing metadata
- accession: 0000950170-24-102554
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/0000950170-24-102554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017024102554/prok-20240822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-102554
- JSON: https://secwatch.observer/filing/0000950170-24-102554.json
- Plain text: https://secwatch.observer/filing/0000950170-24-102554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.